Zeposia was approved in 2020 by FDA and EMA for relapsing MS (#msg-154586608, #msg-154614638). The label expansion to UC is BMY’s first GI-immunology approval.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”